Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 1
R&D Momentum
30/100
Pipeline Velocity
6/100
Trial Completion Rate
100/100
Pipeline Concentration
100/100
Pipeline Freshness
65/100
Activity
Last 14 days
Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)